195 related articles for article (PubMed ID: 24523236)
1. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
[TBL] [Abstract][Full Text] [Related]
2. Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.
Shimonishi N; Ogiwara K; Yoshida J; Horie K; Nakajima Y; Furukawa S; Takeyama M; Nogami K
Blood Adv; 2023 Jun; 7(12):2831-2842. PubMed ID: 36780344
[TBL] [Abstract][Full Text] [Related]
3. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
[TBL] [Abstract][Full Text] [Related]
4. FV and APC resistance: the plot thickens.
Castoldi E
Blood; 2014 Apr; 123(15):2288-9. PubMed ID: 24723678
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
6. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
[TBL] [Abstract][Full Text] [Related]
7. Factor V and thrombotic disease: description of a janus-faced protein.
Nicolaes GA; Dahlbäck B
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
9. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Heeb MJ; Kojima Y; Greengard JS; Griffin JH
Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
[TBL] [Abstract][Full Text] [Related]
10. [Elucidation of an altered anticoagulant function due to Factor V abnormality and development of a simple screening assay for thrombophilia].
Shimonishi N; Nogami K
Rinsho Ketsueki; 2023; 64(7):654-660. PubMed ID: 37544726
[TBL] [Abstract][Full Text] [Related]
11. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
[TBL] [Abstract][Full Text] [Related]
12. Factor V Leiden: a disorder of factor V anticoagulant function.
Castoldi E; Rosing J
Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
[TBL] [Abstract][Full Text] [Related]
13. APC resistance: biological basis and acquired influences.
Castoldi E; Rosing J
J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
[TBL] [Abstract][Full Text] [Related]
14. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
Dahlbäck B
Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
[TBL] [Abstract][Full Text] [Related]
15. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.
Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT
J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588
[TBL] [Abstract][Full Text] [Related]
16. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
Cramer TJ; Griffin JH; Gale AJ
Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Norstrøm E; Thorelli E; Dahlbäck B
Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
[TBL] [Abstract][Full Text] [Related]
18. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
[TBL] [Abstract][Full Text] [Related]
19. Early days of APC resistance and FV Leiden.
Dahlbäck B
Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
[TBL] [Abstract][Full Text] [Related]
20. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors.
Matsumoto T; Nogami K; Shima M
J Thromb Haemost; 2014 Sep; 12(9):1503-12. PubMed ID: 25041532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
